^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    firicabtagene autoleucel (CRG-022)

    i
    Associations
    News

    Trials

    Company:
    Adaptive Biotech, CARGO Therap, Stanford University
    Drug class:
    CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies (NCT06408194)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    05/22/2024
    Initiation :
    05/13/2024
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    CD22
    |
    Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)
    Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (IRB-50836) (NCT04088890)
    Phase 1
    Stanford University
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    09/12/2019
    Primary completion :
    12/30/2024
    Completion :
    12/30/2037
    CD22
    |
    CD22 positive • CD22 expression • CD20 negative
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)
    Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) (NCT05507827)
    Phase 1
    Dr. Melody Smith, MD, MS
    Recruiting
    Last update posted :
    02/20/2024
    Initiation :
    08/18/2022
    Primary completion :
    01/01/2037
    Completion :
    01/01/2037
    CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C
    |
    KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement
    |
    Orca-T • firicabtagene autoleucel (CRG-022)
    CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (NCT04088864)
    Phase 1
    Stanford University
    Active, not recruiting
    Last update posted :
    02/12/2024
    Initiation :
    01/10/2020
    Primary completion :
    10/31/2023
    Completion :
    09/10/2036
    CD22
    |
    CD22 positive • CD22 expression
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)